Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × NSCLC × icotinib × Clear all

Phase

Status

Sponsor Class

OTHER 3 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 21 Brain Neoplasms 4 EGF-R Positive Non-Small Cell Lung Cancer 2 Adenocarcinoma 2 Plasma EGFR Mutation-positive Lung Cancer 1 Pancreatic Neoplasms 1 Nasopharyngeal Carcinoma 1 NSCLC 1 Esophageal Neoplasms 1

Interventions

Carboplatin 6 aflutinib 5 osimertinib 4 Pemetrexed 4 Gefitinib 4 HM781-36B 3 rezivertinib 2 Paclitaxel 2 HMPL-013 2 Cisplatin 2 Albumin-Bound Paclitaxel 2 tipifarnib 1 sulindac sulfone 1 spartalizumab 1 pembrolizumab 1 icotinib 1 aumolertinib 1 apatinib 1 Vinorelbine 1 Taxes 1 Gemcitabine 1 Erlotinib Hydrochloride 1 Docetaxel 1 Clinical Trials, Phase I as Topic 1 Cetuximab 1 CP protocol 1 Bortezomib 1 BID protein, human 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02404675 2017-07-28

INCREASE

Betta Pharmaceuticals Co., Ltd.

Phase 4 Unknown

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡